June 30, 2017

Novocure to Report Second Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
June 30, 2017

Novocure to Report Second Quarter 2017 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and… Read More
learn more
June 28, 2017

Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer

A phase 3 pivotal trial – PANOVA-3 – will test the efficacy of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the company will present three abstracts studying Tumor Treating Fields… Read More
learn more
June 28, 2017

Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer

A phase 3 pivotal trial – PANOVA-3 – will test the efficacy of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the company will present three abstracts studying Tumor Treating Fields… Read More
learn more
June 13, 2017

Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the time of its presentation at the JMP Securities 2017 Life Sciences Conference has changed. The presentation at the conference is now scheduled for 10:30 am EDT on June 21, 2017, in New York. A live audio webcast… Read More
learn more
June 13, 2017

Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the time of its presentation at the JMP Securities 2017 Life Sciences Conference has changed. The presentation at the conference is now scheduled for 10:30 am EDT on June 21, 2017, in New York. A live audio webcast… Read More
learn more
June 8, 2017

First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

The RTOG 3503 phase 2 pilot trial is the first consortium study to test treatment with Optune ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for… Read More
learn more
June 8, 2017

First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma

The RTOG 3503 phase 2 pilot trial is the first consortium study to test treatment with Optune ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for… Read More
learn more
June 5, 2017

Health Care Service Corporation Issues Positive Coverage Decision for Optune

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective… Read More
learn more
June 5, 2017

Health Care Service Corporation Issues Positive Coverage Decision for Optune

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective… Read More
learn more